Neuro-Oncology,
Journal Year:
2018,
Volume and Issue:
20(9), P. 1155 - 1161
Published: May 6, 2018
Monitoring
patient
response
to
treatment
is
challenging
for
most
cancers,
but
it
particularly
difficult
in
glioblastoma
multiform,
the
common
and
aggressive
form
of
malignant
brain
tumor.
These
tumors
exhibit
a
high
degree
heterogeneity
which
may
not
be
reflected
biopsy.
To
determine
if
current
standard
care
effective,
glioma
patients
are
monitored
using
MRI
or
CT
scans,
an
effective
sometimes
misleading
approach
due
phenomenon
pseudoprogression.
As
such,
there
incredible
need
minimally
invasive
"liquid
biopsy"
assist
molecularly
characterizing
while
also
aiding
identification
true
progression
glioblastoma.
This
review
details
status
potential
impact
circulating
tumor
cells,
extracellular
vesicles,
ctDNA,
ctRNA,
putative
biomarkers
found
blood
patients.
mutation-based
therapy
becomes
more
prevalent
gliomas,
blood-based
analyses
offer
non-invasive
method
identifying
mutations.
The
ability
obtain
serial
biopsies"
will
provide
unique
opportunities
study
evolution
mechanisms
resistance
monitor
mutational
changes
therapy.
Gliomas
are
the
most
lethal
primary
brain
tumors
in
adults.
These
highly
invasive
have
poor
5-year
survival
for
patients.
principally
characterized
by
rapid
diffusion
as
well
high
levels
of
cellular
heterogeneity.
However,
to
date,
exact
pathogenic
mechanisms,
contributing
gliomas
remain
ambiguous.
MicroRNAs
(miRNAs),
small
noncoding
RNAs
about
20
nucleotides
length,
known
chief
modulators
different
biological
processes
at
both
transcriptional
and
posttranscriptional
levels.
More
recently,
it
has
been
revealed
that
these
RNA
molecules
essential
roles
tumorigenesis
progression
multiple
cancers,
including
gliomas.
Interestingly,
miRNAs
able
modulate
diverse
cancer-related
such
cell
proliferation
apoptosis,
invasion
migration,
differentiation
stemness,
angiogenesis,
drug
resistance;
thus,
impaired
may
result
deterioration
Additionally,
can
be
secreted
into
cerebrospinal
fluid
(CSF),
bloodstream,
transported
between
normal
tumor
cells
freely
or
exosomes,
converting
them
potential
diagnostic
and/or
prognostic
biomarkers
They
would
also
great
therapeutic
agents,
especially
if
they
could
cross
blood-brain
barrier
(BBB).
Accordingly,
current
review,
contribution
glioma
pathogenesis
is
first
discussed,
then
their
glioma-related
diagnostic/prognostic
highlighted
briefly.
Journal of Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
42(16), P. 1961 - 1974
Published: April 12, 2024
Effective
diagnosis,
prognostication,
and
management
of
CNS
malignancies
traditionally
involves
invasive
brain
biopsies
that
pose
significant
risk
to
the
patient.
Sampling
molecular
profiling
cerebrospinal
fluid
(CSF)
is
a
safer,
rapid,
noninvasive
alternative
offers
snapshot
intracranial
milieu
while
overcoming
challenge
sampling
error
plagues
conventional
biopsy.
Although
numerous
biomarkers
have
been
identified,
translational
challenges
remain,
standardization
protocols
necessary.
Here,
we
systematically
reviewed
141
studies
(Medline,
SCOPUS,
Biosis
databases;
between
January
2000
September
29,
2022)
molecularly
profiled
CSF
from
adults
with
including
glioma,
metastasis,
primary
secondary
lymphomas.
We
provide
an
overview
promising
biomarkers,
propose
reporting
guidelines,
discuss
various
considerations
go
into
biomarker
discovery,
influence
blood-brain
barrier
disruption,
cell
origin,
site
acquisition
(eg,
lumbar
ventricular).
also
performed
meta-analysis
proteomic
data
sets,
identifying
in
establishing
resource
for
research
community.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(5), P. 2464 - 2464
Published: Feb. 20, 2024
Glioblastoma
(GB)
is
the
most
aggressive
and
common
type
of
cancer
within
central
nervous
system
(CNS).
Despite
vast
knowledge
its
physiopathology
histology,
etiology
at
molecular
level
has
not
been
completely
understood.
Thus,
attaining
a
cure
possible
yet
it
remains
one
deadliest
types
cancer.
Usually,
GB
diagnosed
when
some
symptoms
have
already
presented
by
patient.
This
diagnosis
commonly
based
on
physical
exam
imaging
studies,
such
as
computed
tomography
(CT)
magnetic
resonance
(MRI),
together
with
or
followed
surgical
biopsy.
As
these
diagnostic
procedures
are
very
invasive
often
result
only
in
confirmation
presence,
necessary
to
develop
less
prognostic
tools
that
lead
earlier
treatment
increase
patients’
quality
life.
Therefore,
blood-based
biomarkers
(BBBs)
represent
excellent
candidates
this
context.
microRNAs
(miRNAs)
small,
non-coding
RNAs
demonstrated
be
stable
almost
all
body
fluids,
including
saliva,
serum,
plasma,
urine,
cerebrospinal
fluid
(CFS),
semen,
breast
milk.
In
addition,
serum-circulating
exosome-contained
miRNAs
successfully
used
better
classify
subtypes
make
choices
regarding
best
for
specific
cases.
Moreover,
regulate
multiple
target
genes
can
also
act
tumor
suppressors
oncogenes,
they
involved
appearance,
progression,
even
chemoresistance
tumors.
review,
we
discuss
how
dysregulated
early
prognosis
well
markers
subclassify
cases
provide
more
personalized
treatments,
which
may
response
against
GB.
therapeutic
potential
miRNAs,
current
challenges
their
clinical
application,
future
directions
field.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Jan. 25, 2024
Abstract
There
is
great
interest
in
developing
clinical
biomarker
assays
that
can
aid
non-invasive
diagnosis
and/or
monitoring
of
human
diseases,
such
as
cancer,
cardiovascular
disease,
and
neurological
diseases.
Yet
little
known
about
the
longitudinal
stability
miRNAs
plasma.
Here
we
assessed
intraindividual
plasma
from
healthy
adults,
impact
common
factors
(e.g.,
hemolysis,
age)
may
confound
miRNA
data.
We
collected
blood
by
venipuncture
biweekly
over
a
3-month
period
22
research
participants
who
had
fasted
overnight,
isolated
total
RNA,
then
performed
qPCR.
Filtering
normalization
qPCR
data
revealed
amplification
134
miRNAs,
74
which
high
test–retest
reliability
low
percentage
level
drift,
meaning
they
were
stable
an
individual
time
period.
also
determined
that,
nuisance
factors,
hemolysis
tobacco
use
have
greatest
on
levels
variance.
These
findings
support
many
show
including
some
reported
candidate
biomarkers
for
Alzheimer’s
disease.
Neuro-Oncology,
Journal Year:
2018,
Volume and Issue:
20(9), P. 1155 - 1161
Published: May 6, 2018
Monitoring
patient
response
to
treatment
is
challenging
for
most
cancers,
but
it
particularly
difficult
in
glioblastoma
multiform,
the
common
and
aggressive
form
of
malignant
brain
tumor.
These
tumors
exhibit
a
high
degree
heterogeneity
which
may
not
be
reflected
biopsy.
To
determine
if
current
standard
care
effective,
glioma
patients
are
monitored
using
MRI
or
CT
scans,
an
effective
sometimes
misleading
approach
due
phenomenon
pseudoprogression.
As
such,
there
incredible
need
minimally
invasive
"liquid
biopsy"
assist
molecularly
characterizing
while
also
aiding
identification
true
progression
glioblastoma.
This
review
details
status
potential
impact
circulating
tumor
cells,
extracellular
vesicles,
ctDNA,
ctRNA,
putative
biomarkers
found
blood
patients.
mutation-based
therapy
becomes
more
prevalent
gliomas,
blood-based
analyses
offer
non-invasive
method
identifying
mutations.
The
ability
obtain
serial
biopsies"
will
provide
unique
opportunities
study
evolution
mechanisms
resistance
monitor
mutational
changes
therapy.
